OPTA-therapy with iron and erythropoiesis-stimulating agents in chronic kidney disease
|
|
- Natalie Beasley
- 5 years ago
- Views:
Transcription
1 Nephrol Dial Transplant (2007) 22 [Suppl 3]: iii2 iii6 doi: /ndt/gfm014 OPTA-therapy with iron and erythropoiesis-stimulating agents in chronic kidney disease W. H. Ho rl 1, I. C. Macdougall 2, J. Rossert 3 and R. M. Schaefer 4 1 Klinische Abteilung fu r Nephrologie und Dialyse, Medizinische Universita tsklinik III, Wa hringer Gu rtel 18 20, 1090 Wien, Austria, 2 King s College Hospital, London, UK, 3 Paris-Descartes University School of Medicine, AP-HP, Georges Pompidou European Hospital, Paris, France and 4 Universita tsklinikum Mu nster (UKM), Innere Medizin D, Albert-Schweitzer-Straße 33, Mu nster, Germany Introduction Anaemia is a severe problem for patients suffering from chronic kidney disease (CKD). Anaemia is occasionally observed among patients with glomerular filtration rate (GFR) of ml/min (stage III of CKD). Majority of the patients with GFR <30 ml/min exhibit renal anaemia. Diabetic patients may develop anaemia earlier than those with non-diabetic CKD (e.g. GFR of <45 ml/min). The European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure [1] recommend therapy with erythropoiesis stimulating agents (ESA) for patients in whom the haemoglobin concentration is <11 g/dl and additional causes for anaemia, such as iron deficiency, bleeding or malignancy are excluded. Early treatment of anaemia is recommended, since reduced haemoglobin values are associated with left ventricular hypertrophy, increases in morbidity and mortality, increases in the frequency and duration of hospitalization and reduction in quality of life. An adequate measurement of iron status at the beginning of treatment and regular monitoring of iron blood parameters are critical for cost-effective therapy with ESA. Monitoring of iron status Ferritin Serum ferritin levels, as a measure of iron storage in the body, should be quantitated every 3 months in CKD patients who are receiving iron supplementation. This is required to exclude iron deficiency or iron overload. Serum ferritin <15 mg/l in subjects with normal kidney function is an indication of absolute iron deficiency [2]. CKD patients are considered to have absolute iron deficiency if serum ferritin levels are <100 mg/l [3]. The recommended serum ferritin target level in ESA-treated CKD patients receiving iron supplementation is mg/l. In patients on maintenance dialysis therapy, ferritin target level is mg/l [4]. Intravenous administration of iron can result in transient increases in serum ferritin. Therefore, an interval of 1 week should be maintained between intravenous iron administration (i.e mg ferric gluconate or 100 mg iron sucrose) and measurement of serum ferritin. With lower doses of intravenous iron (i.e. 20 mg of ferric gluconate or iron sucrose following each haemodialysis treatment), serum ferritin can directly be measured. In certain conditions, serum ferritin increases due to causes unrelated to an increase in iron storage. Liver disease, malignancy, infection or inflammation can result in increased serum ferritin levels independent of iron status. Transferrin saturation Transferrin saturation (TSAT) is a parameter measuring the degree to which circulating transferrin is loaded with iron. The normal range is between 20 and 45%. Erythropoiesis usually becomes iron-deficient when TSAT falls <20%. Iron supplementation should be initiated around or below these TSAT levels. This is especially important when erythropoiesis is pharmacologically stimulated through ESA treatment. Iron supplementation is mandatory if TSAT levels are <15%. Treatment with higher ESA doses can result in a decrease in TSAT levels even under conditions of sufficient iron storage. This constellation is referred to as»functional iron deficiency«. A low TSAT (<20%) is a good indicator (approximately 90% sensitivity) of iron deficiency but specificity is low (approximately 40%). In the case of»functional iron deficiency«infection or inflammation should be ruled out by measurement of C-reactive protein (CRP). If the CRP is normal, supplementation of vitamin C (1 1.5 g orally per week or mg i.v. after haemodialysis ß The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org
2 OPTA-therapy in CKD depending on the degree of vitamin C deficiency) may result in release of iron from storage reservoirs, increase in haemoglobin levels and decrease in ESA dose [5 7]. Serum iron concentrations follow a circadian rhythm with the highest values occurring in the morning and a nadir in the evening. As a result, the TSAT undergoes a similar circadian rhythm. It is recommended to draw blood for TSAT measurement if possible in the morning. It is difficult to compare TSAT values from blood samples collected at different times of the day. Evaluation of iron supply in the bone marrow percentage of hypochromic red blood cells The appearance of hypochromic red blood cells in the circulation is a sensitive parameter for iron-deficient erythropoiesis and insufficient iron supply in the bone marrow. Ferritin and TSAT are only indirect indicators of the amount of iron available for erythropoiesis. The percentage of hypochromic red blood cells, however, serves as a direct estimation of the iron available for red blood cell development. Circulating hypochromic erythrocytes normally correspond to <2.5% of red blood cells. Values >10% indicate with high sensitivity the occurrence of iron-deficient erythropoiesis. The percentage of hypochromic red blood cells can reach 50% in cases in which extended iron deficient erythropoiesis during ESA treatment occurs [8]. The quantitation of hypochromic red blood cells requires the employment of specific devices (Technikon H*3 or ADVIA-120 analysers) which measure haemoglobin content in single cells by flow cytometry. The parameter is stable over 24 h. Therefore, it is possible to draw a blood sample in an EDTA tube and ship it to a laboratory employing such devices. Haemoglobin content of reticulocytes (CHr) Modern blood cell analysers allow quantitation of reticulocytes as well as analysis of individual cells with respect to cell volume (MCVr) and haemoglobin content of reticulocytes (CHr) [6]. According to Fishbane et al. [9], a CHr <29 pg as measured by a Technikon H*3 blood analyser indicates the presence of iron-deficient erythropoiesis. In contrast to serum ferritin and TSAT, CHr is a direct indicator of iron availability in bone marrow [9]. Recently, Tsuchiya et al. [10] reported that iron-deficient erythropoiesis was already present in haemodialysis patients at CHr values below 32 pg. CHr was measured using an ADVIA-120 system. CHr was shown to be a stable and reliable parameter for estimation of iron availability in the bone marrow. The authors favoured quantitation of haemoglobin and CHr (obtained from a single blood sample) as laboratory parameters necessary for control of iron supplementation and response to epoetin administration [10]. Brugnara et al. [11] compared reticulocyte and red cell measurements iii3 of haemoglobin contents provided by the ADVIA 2120 and Sysmex XE 2100 analysers in 1500 adult and paediatric dialysis patients. The authors demonstrated that with a reticulocyte haemoglobin cut-off level of 27.2 pg, iron deficiency can be diagnosed with a sensitivity of 93.3% and a specificity of 83.2% [11]. In the presence of functional iron deficiency (normal or increased ferritin with simultaneous reduction in TSAT), the determination of the percentage of hypochromic red blood cells and CHr can be used to establish if iron supplementation should be initiated or continued [12]. Practical considerations Serum ferritin and TSAT should be determined before the start of ESA therapy. The response to ESA is optimal when serum ferritin is >200 mg/l and TSAT is >20%. Both parameters should be measured four times per year during maintenance epoetin therapy. The following causes should be excluded if the response to ESA is inadequate (Table 1). The determination of the percentage of hypochromic red blood cells or the haemoglobin content of reticulocytes is diagnostically helpful if functional iron deficiency is suspected. Intravenous iron supplementation is indicated even in the presence of elevated serum ferritin levels if the percentage of hypochromic erythrocytes is >10% and CHr is >29 pg [8]. However, iron supplementation should be used with extreme caution in patients with hepatitis B or C, and should be stopped at least temporarily in those with acute bacterial infections. The number of reticulocytes should be determined if haemoglobin values decrease approximately 0.1 g/dl per day or in cases in which the patient requires more than one unit of packed red cells per week. Reticulocyte values below /ml require testing for the presence of ESA-neutralizing antibodies and bone marrow examination. These analyses must be undertaken to rule out the occurrence of ESAinduced erythroblastopenia (normal bone marrow cellularity with <5% erythroblasts and disturbed differentiation of the erythroid lineage). The number Table 1. Causes of Reduced Response to ESA Absolute iron deficiency, serum ferritin <100 mg/l Functional iron deficiency, serum ferritin >100 mg/l with TSAT <20% and hypochromic erythrocytes >10% or CHr <29 pg Blood loss Infection, inflammation: elevated CRP Pharmacological therapy: high dose ACE-inhibitors and/or AT1-receptor antagonists, cyclophosphamide, azathioprine, mycophenolate-mofetil [13] Inadequate dialysis: Kt/V <1.2, urea reduction rate (URR) <60% Malignant disease Bone marrow diseases: plasmacytoma, myelodysplastic syndrome, leukaemia
3 iii4 of leucocytes and thrombocytes do not decrease in this disease state. Iron therapy Iron requirements Approximately 150 mg iron is required for each 1 g/dl increase in haemoglobin concentration. A typical correction of 3 4 g/dl requires mg of iron. During the maintenance phase of ESA treatment, the loss of blood resulting from the haemodialysis procedure increases the iron requirement to 1 3 g per year. Iron supplementation at such quantities is only possible through intravenous administration. The majority of patients cannot ingest such high doses of iron in oral form without intestinal adverse effects. The risk of iatrogenic iron overload with intravenous iron administration is low if regular measurements of serum ferritin are carried out [14]. Iron requirements for patients with chronic renal insufficiency (CKD stages 2 4), renal transplant patients and peritoneal dialysis patients are lower than those of patients undergoing haemodialysis. Pre-dialysis and renal transplant patients mostly suffer from less-pronounced anaemia, and iron loss does not occur in peritoneal dialysis patients as compared to haemodialysis patients. In those patients, oral iron supplementation ( mg iron per day) can be tried. If iron status does not improve at such a dosage, or if oral ingestion results in intestinal sideeffects, then iron can be administered intravenously. Iron preparations for intravenous administration There are different iron preparations for intravenous injection available in Europe, varying from country to country. In Germany, for example, there are three different products available:: Ferrlecit Õ, Venofer Õ and CosmoFer Õ. Ferrlecit Õ is an iron-(iii)-gluconate complex, Venofer Õ consists of iron-(iii)-hydroxide-sucrose and CosmoFer Õ is an iron-(iii)-hydroxide-dextrancomplex. The three compounds differ with regard to stability and incidence of anaphylactoid reactivity. Iron dextran is more stable than iron sucrose which in turn is more stable than ferric gluconate. The stability of the iron complexes is clinically relevant because stable complexes are less likely to lead to toxicity. This is reflected in the maximal single dosage recommendations: CosmoFer Õ 20 mg/kg body weight; Venofer Õ 500 mg; Ferrlecit Õ 62.5 mg [15 17]. Intravenously administered iron preparations can potentially induce anaphylactic reactions. According to the manufacturers, the frequency of anaphylactic reactions is <1/100 with CosmoFer Õ, <1/1000 with Ferrlecit Õ and <1/ with Venofer Õ. Some manufacturers suggest administration of a small test dose prior to the first intravenous iron administration. The injection should be carried out with the patient in a supine position. W. H. Ho rl et al. Dosage and frequency of administration The dosage of iron during the correction phase of anaemia therapy in haemodialysis patients should correspond to a total of 1000 mg iron (over a period of 6 12 weeks) to ensure that iron supply is sufficient to fill iron stores and to optimize ESA-stimulated erythropoiesis. Iron requirements during the maintenance phase of therapy vary considerably. Various therapeutic regimens can be used (Table 2). The dose spectrum varies from small amounts of iron (10 20 mg) at each dialysis session to 250 mg of iron sucrose as a single infusion once monthly [18]. Agarwal et al. [19] administered 100 mg of iron sucrose over 5 min, whereas Macdougall and Roche [20] administered 200 mg of iron sucrose as an intravenous bolus injection of 2 min in CKD patients. On the other hand, Leehey et al. [21] infused 125 mg of ferric gluconate over 1 h and 250 mg of ferric gluconate over 2 h in patients with CKD. These data indicate an enormous flexibility in the actual dose regimen. Intravenous iron has been linked to infection risk, systemic inflammation, tissue oxidation and atherosclerosis (for review [14]). A recent multicentre trial of Aronoff et al. [22] demonstrated that iron sucrose is safe when given as treatment for iron deficiency or for maintenance of iron stores. Iron requirements of pre-dialysis patients, peritoneal dialysis patients and renal transplant patients The iron requirements of pre-dialysis patients, peritoneal dialysis patients and renal transplant patients are usually lower than those of haemodialysis patients, since anaemia is usually less pronounced, and haemodialysis-associated blood loss does not occur. In long-term renal transplant recipients, the prevalence of iron deficiency, as indicated by a percentage of hypochromic red blood cells of 2.5%, was 20.1% [23]. Iron requirements are lower both during the correction phase and during the maintenance phase of ESA therapy. Iron can be administered in an oral form at the outset of treatment. In most of the studies, intravenous iron therapy was more effective than oral iron supplementation [24 29]. Table 2. Intravenous iron dosage and administration frequency in haemodialysis patients during maintenance of ESA-therapy Absolute iron deficiency mg Fe/dialysis session or mg Fe in 6 10 weeks Maintenance phase mg Fe sucrose/dialysis session or mg Fe gluconate/week or mg Fe gluconate/week or mg Fe sucrose/month or mg Fe dextran (low-molecular weight)/month > or mg Fe sucrose/month (depending on ferritin level) Hb correction phase 150 mg Fe/Hb increase of 1 g/dl
4 OPTA-therapy in CKD Guidelines for intravenous iron injection The available iron preparations allow safe and efficient intravenous administration of iron. Caution must be used to ensure strictly intravenous application. Intravenous iron must be injected slowly enough to mitigate any risk of side effect. Injection time should be even longer with high iron doses. Intravenous iron injection in haemodialysis patients is for the most part uncomplicated because patients usually have suitable intravenous access. Iron injection can proceed slowly during the dialysis session. iii5 growth of many microorganisms. Intravenous iron substitution should proceed conservatively in patients with permanent dialysis catheters (higher risk of infection) and/or in the presence of hepatitis B and/or hepatitis C infection (more unfavourable prognosis?). Patients with chronic inflammatory diseases (e.g. chronic arthritis, Crohn s disease) can receive intravenous iron therapy in a normal manner. Conflict of interest statement. None declared. Importance of intravenous iron therapy Intravenous iron supplementation is required to fill depleted iron stores in a short period of time and to provide the iron required for increased haemoglobin synthesis associated with ESA-stimulated erythropoiesis. It has been shown in a number of studies [30] that the most decisive factor for optimal utilization of epoetin is an adequate provision of iron. The studies by Sunder-Plassmann and Ho rl [31], Besarab et al. [32] as well as De Vita et al. [33] have shown impressively the large potential to reduce effective ESA doses when existing iron deficiency is corrected. Summary Serum ferritin concentration and TSAT are used as routine diagnostic parameters for the assessment of iron status during ESA therapy in CKD patients. The analyses of the percentage of hypochromic red blood cells or of reticulocyte haemoglobin content, although not available in many clinical centres, facilitate the decision to proceed with intravenous iron substitution in the presence of hyperferritinaemia and low TSAT. The risk of iron overloading is low if parenteral iron substitution therapy is adapted to haemodialysisassociated iron losses (1 3 g/year). The iron requirements of pre-dialysis patients, peritoneal dialysis patients and renal transplant patients are lower than those of haemodialysis patients. An initial course of oral iron substitution may be warranted in these patients. However, most of those patients must be switched eventually to intravenous iron administration, since oral administration becomes ineffective. Serum ferritin should be regularly measured (four times per year) during intravenous iron therapy. Ferritin concentrations above 500 mg/l (in the presence of normal CRP) should be avoided over an extended time period to prevent iatrogenic iron overloading. Iron therapy should be discontinued (while still continuing ESA therapy) in the vast majority of the patients if ferritin concentrations increase above 500 mg/l. Iron therapy should also be discontinued during acute bacterial infections since iron stimulates References 1. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 [Suppl 2]: ii1 ii Galloway MJ, Smellie WS. Investigating iron status in microcytic anaemia. Br Med J 2006; Ho rl WH, Cavill I, Macdougall IC, Schaefer RM, Sunder- Plassmann G. How to diagnose and correct iron deficiency during r-huepo therapy a consensus report. Nephrol Dial Transplant 1996; 11: K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 2006; 47 [Suppl 3]: S11 S Tarng DC, Huang TP. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. Nephrol Dial Transplant 1998; 13: Ho rl WH. Is there a role for adjuvant therapy in patients being treated with epoetin? Nephrol Dial Transplant 1999; 14 [Suppl 2]: Keven K, Kutlay S, Nergizogly G, Ertu rk S. Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. Am J Kidney Dis 2003; 41: Schaefer RM, Schaefer L. Hypochromic red blood cells and reticulocytes. Kidney Int 1999; 55 [Suppl 69]: S44 S48 9. Fishbane S, Shapiro W, Dutka P, Valenzuela OF, Faubert J. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 2001; 60: Tsuchiya K, Okano H, Teramura M et al. Content of reticulocyte hemoglobin is a reliable tool for determining iron deficiency in dialysis patients. Clin Nephrol 2003; 59: Brugnara C, Schiller B, Moran J. Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states. Clin Lab Haematol 2006; 28: Cullen P, So ffker J, Ho pfl M et al. Hypochromic red cells and reticulocyte haemglobin content as markers of iron-deficient erythropoiesis in patients undergoing chronic haemodialysis. Nephrol Dial Transplant 1999; 14: Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group. Transplantation 1999; 68: Ho rl WH. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol 2007; 18: Fachinformation: CosmoFer Õ. GRY-Pharma GmbH, Juni Fachinformation: Ferrlecit Õ. Aventis Pharma Deutschland GmbH, Dezember Fachinformation: Venofer Õ. Fresenius Medical Care Deutschland GmbH, Juni Kosch M, Bahner U, Bettger H, Matzkies F, Teschner M, Schaefer RM. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate
5 iii6 (Ferrlecit) in haemodialysis patients treated with rhuepo. Nephrol Dial Transplant 2001; 16: Agarwal R, Vasavada N, Sachs NG et al. Oxidative stress in renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65: Macdougall IC, Roche A. Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections. AmJKidneyDis2005; 46: Leehey DJ, Palubiak DJ, Chebrrolu S, Agarwal R. Sodium ferric gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: a pilot study. Nephrol Dial Transplant 2005; 20: Aronoff GR, Bennett WM, Blumenthal S et al. Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. Kidney Int 2004; 66: Lorenz M, Kletzmayr J, Perschl A, Furrer A, Ho rl WH, Sunder-Plassmann G. Anaemia and iron deficiencies among long-term renal transplant recipients. J Am Soc Nephrol 2002; 13: Macdougall IC, Tucker B, Thompson J et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50: Ahsan M. Intravenous infusion of total dose iron is superior to oral iron in treatment of anaemia in peritoneal dialysis patients: a single-center comparative study. J Am Soc Nephrol 1998; 9: W. H. Ho rl et al. 26. Vychytil A, Haag-Weber M. Iron status and iron supplementation in peritoneal dialysis patients. Kidney Int Suppl 1999; 69: S71 S Johnson DW, Herzig KA, Gissane R et al. Oral versus intravenous iron supplementation in peritoneal dialysis patients. Perit Dial 2001; 21 [Suppl 3]: S231 S Van Wyck DB, Roppolo M, Martinez CA et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 2005; 68: Agarwal R, Rizkala AR, Bastani B et al. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 2006; 26: Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 2001; 38: Sunder-Plassmann G, Ho rl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 1995; 10: Besarab A, Amin N, Ahsan M et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000; 11: DeVita MV, Frumkin D, Mittal S et al. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin Nephrol 2003; 60:
ANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationHemodialysis patients with endstage
Insights into Achieving Target Hemoglobin Levels: Increasing the Serum Ferritin Parameter Scott Bralow, DO Dr. Scott Bralow is the Medical Director of the Renal Center of Philadelphia. Evidence suggests
More informationPublished Online 2013 July 24. Research Article
Nephro-Urology Monthly. 2013 September; 5(4):913-7. Published Online 2013 July 24. DOI: 10.5812/numonthly.12038 Research Article Comparative Study of Intravenous Iron Versus Intravenous Ascorbic Acid for
More informationferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharma UK Ltd
Resubmission ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharma UK Ltd 06 May 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationADVANCES. Annual reports from the Centers for. In Anemia Management. Anemia Management in the United States: Is There Opportunity for Improvement?
ADVANCES Vol. 1 No.1 22 We are pleased to introduce our newest NPA publication, Advances in Anemia Management. This quarterly publication will address contemporary issues relating to the treatment of anemia
More informationIntravenous Iron Requirement in Adult Hemodialysis Patients
Intravenous Iron Requirement in Adult Hemodialysis Patients Timothy V. Nguyen, PharmD The author is a clinical pharmacy specialist with Holy Name Hospital in Teaneck, New Jersey. He is also an adjunct
More informationferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals
ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals 17 December 2010 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationNew Aspects to Optimize Epoetin Treatment with Intravenous Iron Therapy in Hemodialysis Patients
23. Berliner DialyseSeminar 1.-4. Dezember 2010 New Aspects to Optimize Epoetin Treatment with Intravenous Iron Therapy in Hemodialysis Patients George R. Aronoff, MD, MS, FACP Professor of Medicine and
More informationIntravenous Iron: A Good Thing Made Better? Marilyn Telen, MD Wellcome Professor of Medicine Duke University
Intravenous Iron: A Good Thing Made Better? Marilyn Telen, MD Wellcome Professor of Medicine Duke University Use of IV Iron There are increasing data regarding safety of IV iron. IV iron is superior to
More informationEffective Health Care Program
Comparative Effectiveness Review Number 83 Effective Health Care Program Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease Executive Summary Background Chronic
More informationComment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease.
Comment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease. Goldsmith D, Blackman A, Gabbay F, June 2013 Kidney Disease: Improving Global Outcomes (KDIGO)
More informationK atching Up with KDOQI: Clinical Practice Guidelines & Clinical Practice Recommendations for Anemia of Chronic Kidney Disease 2006
K atching Up with KDOQI: Clinical Practice Guidelines & Clinical Practice Recommendations for Anemia of Chronic Kidney Disease 2006 Why new guidelines? Rationale for KDOQI Anemia 2006 Expand scope to all
More informationMaintenance intravenous iron therapy in pediatric hemodialysis patients Morgan H E, Gautam M, Geary D F
Maintenance intravenous iron therapy in pediatric hemodialysis patients Morgan H E, Gautam M, Geary D F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion
More informationPredictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation
http://www.kidney-international.org & 2007 International Society of Nephrology original article Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low
More informationSummary of Recommendation Statements Kidney International Supplements (2012) 2, ; doi: /kisup
http://www.kidney-international.org & 2012 KDIGO Summary of Recommendation Statements Kidney International Supplements (2012) 2, 283 287; doi:10.1038/kisup.2012.41 Chapter 1: Diagnosis and evaluation of
More informationIron Markers in Patients with Advance Chronic Kidney Disease on First Dialysis at Shaikh Zayed Hospital, Lahore
Proceeding S.Z.P.G.M.I. Vol: 29(2): pp. 83-87, 2015. Iron Markers in Patients with Advance Chronic Kidney Disease on First Dialysis at Waqar Ahmad, Muhammad Rizwan Ul Haque, Abad Ur Rehman and Sammiullah
More informationManagement of anemia in CKD
Management of anemia in CKD Pierre Cochat, MD PhD Professor of Pediatrics Chair, Pediatrics & Pediatric Surgery Department Head, Center for Rare Renal Diseases Néphrogones Hospices Civils de Lyon & University
More informationUtilizing Sysmex RET He to Evaluate Anemia in Cancer Patients
Utilizing Sysmex RET He to Evaluate Anemia in Cancer Patients Ellinor I. Peerschke, Ph.D., F.A.H.A. Vice Chair, Laboratory Medicine Chief, Hematology & Coagulation Laboratory Services Memorial Sloan Kettering
More informationResearch Article Erythrocyte and Reticulocyte Indices on the LH 750 as Potential Markers of Functional Iron Deficiency
Anemia Volume 2010, Article ID 625919, 7 pages doi:10.1155/2010/625919 Research Article Erythrocyte and Reticulocyte Indices on the LH 750 as Potential Markers of Functional Iron Deficiency Eloísa Urrechaga,
More informationAnemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN
Anemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN Professor of Medicine Director, Division of Nephrology and Hypertension University of Oklahoma College of Medicine Definition
More informationORIGINAL ARTICLE. Evaluation of Effect of Ascorbic Acid on Ferritin and Erythropoietin Resistance in Patients of Chronic Kidney Disease
32 Evaluation of Effect of Ascorbic Acid on Ferritin and Erythropoietin Resistance in Patients of Chronic Kidney Disease N Nand 1, S Venu 2, AR Deshmukh 2, R Mittal 2 ORIGINAL ARTICLE Abstract This study
More informationStages of chronic kidney disease
For mass reproduction, content licensing and permissions contact Dowden Health Media. Jonathan J. Taliercio, DO Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, Ohio talierj@ccf.org
More informationThe safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease
Kidney International, Vol. 64, Supplement 87 (2003), pp. S72 S77 The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease DANIEL A. BLAUSTEIN, MICHAEL
More informationNational Institute for Health and Care Excellence
National Institute for Health and Care Excellence 2-year surveillance (2017) Chronic kidney disease: managing anaemia (2015) NICE guideline NG8 Appendix A3: Summary of new evidence from surveillance Diagnostic
More informationiron III isomaltoside 1000 (contains 50mg iron per ml) (Diafer ), solution for injection SMC No. (1177/16) Pharmacosmos UK Limited
Re-submission iron III isomaltoside 1000 (contains 50mg iron per ml) (Diafer ), solution for injection SMC No. (1177/16) Pharmacosmos UK Limited 13 January 2017 The Scottish Medicines Consortium (SMC)
More informationNURSE OR PHARMACIST-LED ANEMIA MANAGEMENT PROTOCOL
CANN-NET ANEMIA MANAGEMENT FOR HEMODIALYSIS CENTRES NURSE OR PHARMACIST-LED ANEMIA MANAGEMENT PROTOCOL TABLE OF CONTENTS: Hemoglobin Status Assessment ------------------------------------------- Page 1
More informationThe efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis
Nephrol Dial Transplant (2006) 21: 2846 2850 doi:10.1093/ndt/gfl387 Advance Access publication 5 August 2006 Original Article The efficacy of intravenous darbepoetin alfa administered once every 2 weeks
More informationTitle: Parenteral Iron Therapy for Anemia: A Clinical and Cost-Effectiveness Review
Title: Parenteral Iron Therapy for Anemia: A Clinical and Cost-Effectiveness Review Date: 14 February 2008 Context and policy issues: Anemia is a complication of chronic diseases and commonly occurs in
More informationEfficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia. Ioannis Griveas, MD, PhD
Efficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia Ioannis Griveas, MD, PhD Anaemia is a state in which the quality and/or quantity of circulating red blood cells are below
More informationAdvanced Level. Understanding Iron Deficiency Anaemia in Chronic Kidney Disease Information at Advanced Level. Karen Jenkins RN, PGDip HE, MSc
Advanced Level European Dialysis and Transplant Nurses Association/ European Renal Care Association Understanding Iron Deficiency Anaemia in Chronic Kidney Disease Information at Advanced Level. Karen
More informationEpogen / Procrit. Epogen / Procrit (epoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.06 Section: Prescription Drugs Effective Date: April1, 2014 Subject: Epogen / Procrit Page: 1 of 7
More informationCosmoFer. Dose Selection and Calculation Guide for intravenous administration. Low molecular weight iron dextran. Revised TDI tables
CosmoFer Low molecular weight iron dextran Dose Selection and Calculation Guide for intravenous administration Revised TDI tables low Mw iron dextran Before prescribing CosmoFer please refer to full local
More informationAranesp. Aranesp (darbepoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.01 Subject: Aranesp Page: 1 of 6 Last Review Date: September 15, 2017 Aranesp Description Aranesp
More informationLife Science Journal 2013;10(4)
Short Term Low Dose Intravenous Ascorbic Acid in Functional Iron Deficiency Anemia in Hemodialysis Patients Magdy El-Sharkawy¹, Walid Bichari ¹, Mostafa Kamel ¹ and Hanaa Fathey ² ¹ Internal Medicine and
More informationNATIONAL QUALITY FORUM Renal EM Submitted Measures
NATIONAL QUALITY FORUM Renal EM Submitted Measures Measure ID/ Title Measure Description Measure Steward Topic Area #1662 Percentage of patients aged 18 years and older with a diagnosis of CKD ACE/ARB
More informationThe safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients
Kidney International, Vol. 68 (2005), pp. 1801 1807 The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients BRUCE S. SPINOWITZ, MICHAEL H. SCHWENK, PAULA M. JACOBS, W.
More informationRENAL ANAEMIA. South West Renal Training Scheme Cardiff October 2018
RENAL ANAEMIA South West Renal Training Scheme Cardiff October 2018 Dr Soma Meran Clinical Senior Lecturer and Honorary Consultant Nephrologist, University Hospital of Wales. Aims Biology of renal anaemia
More informationDrugs Used in Anemia
Drugs Used in Anemia Drugs of Anemia Anemia is defined as a below-normal plasma hemoglobin concentration resulting from: a decreased number of circulating red blood cells or an abnormally low total hemoglobin
More informationIron Supplementation and Erythropoiesis-Stimulatory Agents in the Treatment of Cancer Anemia
Iron Supplementation and Erythropoiesis-Stimulatory Agents in the Treatment of Cancer Anemia Paolo Pedrazzoli, MD 1, Giovanni Rosti, MD 2, Simona Secondino, MD 1, and Salvatore Siena, MD 1 Unresponsiveness
More informationIron metabolism anemia and beyond. Jacek Lange Perm, 8 October 2016
Iron metabolism anemia and beyond Jacek Lange Perm, 8 October 2016 1 Overview 1. Iron metabolism 2. CKD Chronic Kidney Disease 3. Iron deficiency beyond anemia and CKD 4. Conclusions 2 Why iron deficiency
More informationRenal association clinical practice guideline on Anaemia of Chronic Kidney Disease
Mikhail et al. BMC Nephrology (2017) 18:345 DOI 10.1186/s12882-017-0688-1 CORRESPONDENCE Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease Ashraf Mikhail 1*, Christopher
More informationEffect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial
NDT Advance Access published November 13, 2014 Nephrol Dial Transplant (2014) 0: 1 8 doi: 10.1093/ndt/gfu357 Original Article Effect of oral liposomal iron versus intravenous iron for treatment of iron
More informationInternationally indexed journal
www.ijpbs.net Internationally indexed journal Indexed in Chemical Abstract Services (USA), Index coppernicus, Ulrichs Directory of Periodicals, Google scholar, CABI,DOAJ, PSOAR, EBSCO, Open J gate, Proquest,
More informationYEAR III Pharm.D Dr. V. Chitra
YEAR III Pharm.D Dr. V. Chitra Anemia can be defined as a reduction in the hemoglobin,hematocrit or red cell number. In physiologic terms an anemia is any disorder in which the patient suffers from tissue
More informationGUIDELINES FOR ADMINISTRATION OF INTRAVENOUS IRON IN ADULTS WITH CHRONIC KIDNEY DISEASE
GUIDELINES FOR ADMINISTRATION OF INTRAVENOUS IRON IN ADULTS WITH CHRONIC KIDNEY DISEASE Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if
More informationEvaluation of the effect of oral versus intravenous iron treatments on anemia in patients with chronic kidney diseases.
Evaluation of the effect of oral versus intravenous iron treatments on anemia in patients with chronic kidney diseases. Arif Sami Malik FICMS. Abstract Background:Correction of anemia as a result of renal
More informationGuideline Summary NGC-6019
NGC banner Guideline Summary NGC-6019 Guideline Title (1) KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. (2) 2007 update of hemoglobin target.
More informationIs Iron Sucrose (Venofer) a Safe Treatment for People with Chronic Kidney Disease?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Is Iron Sucrose (Venofer) a Safe Treatment
More informationManaging Anaemia in IBD
Oxford Inflammatory Bowel Disease & Hepatology MasterClass Managing Anaemia in IBD Dr Alex Kent Senior Research Fellow Disclosures WHO Classification of Anaemia Normal haemoglobin and haematocrit levels
More informationWORLD JOURNAL OF PHARMACOLOGICAL RESEARCH AND TECHNOLOGY Anemia in CKD: A Review
Review Article ISSN: 2347-4882 WORLD JOURNAL OF PHARMACOLOGICAL RESEARCH AND TECHNOLOGY Anemia in CKD: A Review Supriya Mor* 1, Prashant Mor 2, Anupama Diwan 1 1 School of Pharmaceutical Sciences, Apeejay
More informationSYNOPSIS. Issue Date: 04 February 2009 Document No.: EDMS -USRA
SYNOPSIS Issue Date: 04 February 2009 Document No.: EDMS -USRA-10751204 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Johnson & Johnson Pharmaceutical Research & Development,
More informationThe FIND-CKD Study Background Study design (Results)
The FIND-CKD Study Background Study design (Results) The FIND-CKD Study An open-label, multicentre, randomized, 3 arm study comparing the 12-month efficacy and safety of Ferric carboxymaltose (FCM, Ferinject
More informationClinical Study Serum Hepcidin Levels and Reticulocyte Hemoglobin Concentrations as Indicators of the Iron Status of Peritoneal Dialysis Patients
International Nephrology Volume 2012, Article ID 239476, 7 pages doi:10.1155/2012/239476 Clinical Study Serum Hepcidin Levels and Reticulocyte Hemoglobin Concentrations as Indicators of the Iron Status
More informationFuture Direction of Anemia Management in ESRD. Jay B. Wish, MD 2008 Nephrology Update March 20, 2008
Future Direction of Anemia Management in ESRD Jay B. Wish, MD 2008 Nephrology Update March 20, 2008 The Evidence Normal Hct Study and CHOIR demonstrate adverse outcomes in ESA patients with target Hgb
More informationCPR 3.5. EVALUATING AND CORRECTING PERSISTENT FAILURE TO REACH OR MAINTAIN INTENDED HB
CPR 3.5. EVALUATING AND CORRECTING PERSISTENT FAILURE TO REACH OR MAINTAIN INTENDED HB Although relative resistance to the effect of ESAs is a common problem in managing the anemia of patients with CKD
More informationEvidence-Based Hematological Solutions
Evidence-Based Hematological Solutions Beyond the Routine CBC Objectives Describe novel hematology parameters and their derivation. Investigate the evidence for their clinical utility. Discuss how new
More informationLaboratory diagnosis of iron deficiency: The interpretation of automated counting parameters. Dr Wayne Thomas Derriford Hospital, Plymouth
Laboratory diagnosis of iron deficiency: The interpretation of automated counting parameters. Dr Wayne Thomas Derriford Hospital, Plymouth Why does it matter? Over 30% of the Worlds population are anaemic,
More informationTitle:Trends in Anemia Management in US Hemodialysis Patients
Author's response to reviews Title:Trends in Anemia Management in US Hemodialysis Patients 2004-2010 Authors: Dana C Miskulin (dmiskulin@tuftsmedicalcenter.org) Jing Zhou (jzhou9@jhmi.edu) Navdeep Tangri
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 November 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 November 2010 Examination of the dossier of the proprietary medicinal product included on the list for a limited
More informationOral Iron Safe, Effective, and Misunderstood Duke Debates 2017
Oral Iron Safe, Effective, and Misunderstood Duke Debates 2017 John Strouse, MD, PhD Instructor (temp) Medicine and Pediatrics Director, Adult Sickle Cell Program April 20, 2017 1 Disclosures I have no
More informationThe Changing Clinical Landscape of Anemia Management in Patients With CKD: An Update From San Diego Presentation 1
Presentation 1 The following is a transcript from a web-based CME-certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by educational grants
More informationYoung Ki Lee, Sung Gyun Kim, Jang Won Seo, Ji Eun Oh, Jong-Woo Yoon, Ja-Ryong Koo, Hyung Jik Kim and Jung Woo Noh
Nephrol Dial Transplant (2008) 23: 3240 3246 doi: 10.1093/ndt/gfn255 Advance Access publication 9 May 2008 Original Article A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection
More informationStudy of Management of anemia in Chronic Kidney Disease Patients
Review Article Study of Management of anemia in Chronic Kidney Disease Patients Meby Susan Mathew, Nama Ravi Sneha Keerthi, Neelathahalli Kasturirangan Meera* Meera N.K, Visveswarapura Institute of Pharmaceutical
More informationNephrology Dialysis Transplantation
Nephrol Dial Transplant (2000) 15 [Suppl 4]: 33 42 Nephrology Dialysis Transplantation European Best Practice Guidelines 9 13 Anaemia management Claude Jacobs, Walter H. Hörl, Iain C. Macdougall, Fernando
More informationClinical Policy: Iron Sucrose (Venofer) Reference Number: CP.PHAR.167
Clinical Policy: (Venofer) Reference Number: CP.PHAR.167 Effective Date: 03/16 Last Review Date: 03/17 Revision Log Coding Implications See Important Reminder at the end of this policy for important regulatory
More informationNo Disclosures 03/20/2019. Learning Objectives. Renal Anemia: The Basics
Renal Anemia: The Basics Meredith Atkinson, M.D., M.H.S. Associate Professor of Pediatrics Johns Hopkins School of Medicine 16 March 2019 No Disclosures Learning Objectives At the end of this session the
More informationIron deficiency anemia in chronic kidney disease: Uncertainties and cautions
Scholarly Review Iron deficiency anemia in chronic kidney disease: Uncertainties and cautions Rajiv AGARWAL Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans
More informationClinical Policy: Ferumoxytol (Feraheme) Reference Number: CP.PHAR.165
Clinical Policy: (Feraheme) Reference Number: CP.PHAR.165 Effective Date: 03/16 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationORIGINAL PAPER. Introduction
ORIGINAL PAPER Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study F. Dellanna, 1
More informationConversion Dosing Guide:
Conversion Dosing Guide: From epoetin alfa to Aranesp in patients with anemia due to CKD on dialysis Indication Aranesp (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney
More informationARE ALL IRON PREPARATIONS EQUAL? Walter H. Hörl, Vienna, Austria. Chair: Pieter Evenepoel, Leuven, Belgium Kostas Siamopoulos, Ioannina, Greece
ARE ALL IRON PREPARATIONS EQUAL? Walter H. Hörl, Vienna, Austria Chair: Pieter Evenepoel, Leuven, Belgium Kostas Siamopoulos, Ioannina, Greece Prof. Walter H. Hörl Division of Nephrology and Dialysis Departm
More informationIRON DEFICIENCY / ANAEMIA ANTHONY BEETON
IRON DEFICIENCY / ANAEMIA ANTHONY BEETON HYPOXIA 1-2 mg IRON Labile iron Body iron ± 3 4 g Liver and the reticuloendothelial system and spleen (approximately 200 300 mg in adult women and 1 g in adult
More informationEffect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial
Nephrol Dial Transplant (2015) 30: 645 652 doi: 10.1093/ndt/gfu357 Advance Access publication 13 November 2014 Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia
More informationVitamin C plasma level and response to erythropoietin in patients on maintenance haemodialysis
Nephrol Dial Transplant (2004) 19: 2319 2324 DOI: 10.1093/ndt/gfh260 Original Article Vitamin C plasma level and response to erythropoietin in patients on maintenance haemodialysis Robert Deicher 1, Farzad
More informationStrategies for iron supplementation: Oral versus intravenous
Kidney International, Vol. 55, Suppl. 69 (1999), pp. S-61 S-66 IRON THERAPY IN RENAL FAILURE PATIENTS Strategies for iron supplementation: Oral versus intravenous IAIN C. MACDOUGALL Department of Renal
More informationAssessing Iron Status in CKD Patients: New Laboratory Parameters
14 Assessing Iron Status in CKD Patients: New Laboratory Parameters Eloísa Urrechaga 1, Luís Borque 2 and Jesús F. Escanero 2 1 Laboratory, Hospital Galdakao, Usansolo Galdakao, Vizcaya 2 Department of
More informationInjectable Iron Products
Injectable Iron Products Allyson Gabbard, Pharm.D. PGY1 Pharmacy Specialist Resident INTEGRIS Baptist Medical Center 1 Learning Objectives Compare and contrast the different injectable iron products. List
More informationClinical Policy: Ferric Carboxymaltose (Injectafer) Reference Number: CP.PHAR.234
Clinical Policy: (Injectafer) Reference Number: CP.PHAR.234 Effective Date: 06/16 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important
More informationMarkers of iron status in chronic kidney disease
Scholarly Review Markers of iron status in chronic kidney disease Adam E. GAWEDA Department of Medicine, University of Louisville, Louisville, Kentucky, USA Abstract Anemia is one of the main comorbidities
More informationNURSE OR PHARMACIST-LED ANEMIA MANAGEMENT PROTOCOL EDUCATIONAL PACKAGE TABLE OF CONTENTS:
CANN-NET ANEMIA MANAGEMENT FOR HEMODIALYSIS CENTRES NURSE OR PHARMACIST-LED ANEMIA MANAGEMENT TABLE OF CONTENTS: PROTOCOL EDUCATIONAL PACKAGE Page 2: CANN-NET Anemia Management Protocol: Educational Document
More informationMicrocytic Hypochromic Anemia An Approach to Diagnosis
Microcytic Hypochromic Anemia An Approach to Diagnosis Decreased hemoglobin synthesis gives rise to microcytic hypochromic anemias. Hypochromic anemias are characterized by normal cellular proliferation
More informationIron Therapy. Product Monograph. Version 1.4. low Mw iron dextran
Iron Therapy low Mw iron dextran Product Monograph Version 1.4 Effective and flexible... CosmoFer IV iron therapy significantly increases the response to rhuepo, compared to oral iron supplementation 33,35
More informationReference ID:
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TRIFERIC safely and effectively. See full prescribing information for TRIFERIC. TRIFERIC (ferric
More informationAjay Gupta 1,2, Vivian Lin 2, Carrie Guss 2, Raymond Pratt 2, T. Alp Ikizler 3 and Anatole Besarab 4,5
http://www.kidney-international.org 25 International Society of Nephrology clinical trial OPEN see commentary on page 946 Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating
More informationNorthern Treatment Advisory Group
Northern Treatment Advisory Group Ferric Maltol (Feraccru ) for the treatment of iron deficiency Lead author: Daniel Hill Regional Drug & Therapeutics Centre (Newcastle) September 2018 2018 Summary Iron
More informationVery low doses of direct intravenous iron in each session as maintenance therapy in haemodialysis patients
Research Article imedpub Journals http://www.imedpub.com Journal of Clinical & Experimental Nephrology Abstract Very low doses of direct intravenous iron in each session as maintenance therapy in haemodialysis
More informationEFFECTIVE SHARE CARE AGREEMENT
Specialist details Patient identifier Name: Tel: EFFECTIVE SHARE CARE AGREEMENT For the specialist use of Erythropoietin Stimulating Agent (ESA) Therapy (formerly known as EPO) for the correction of Anaemia
More informationAmong patients with peritoneal dialysis dependent
CJASN epress. Published on March 29, 2006 as doi: 10.2215/CJN.01541005 Effect of Intravenous Iron Sucrose in Peritoneal Dialysis Patients Who Receive Erythropoiesis-Stimulating Agents for Anemia: A Randomized,
More informationIn-House. Solution for Injection A dark brown coloured, slightly viscous solution filled in ampoule.
Iron Sucrose Injection USP 20 mg/ml Iron sucrose Eq. to Elemental Iron 01 Iron sucrose Eq. to Elemental Iron In-House 02 Sodium Hydroxide BP 333.0 Eq. to 20.00 Q.S. to adjust ph Iron supplement ph Adjustment
More information1 INDICATIONS AND USAGE. 1.1 Limitation of Use FULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TRIFERIC safely and effectively. See full prescribing information for TRIFERIC. TRIFERIC (ferric
More informationRole of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure
ORIGINAL ARTICLE JIACM 2009; 10(1 & 2): 18-22 Abstract Role of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure N Nand*, HK Aggarwal**,
More informationImpact of correction of anemia on major complication of chronic renal diseases
Original article: Impact of correction of anemia on major complication of chronic renal diseases Md Hamid Ali, Atanu Roy Chaudhry, Kapildev Mondal, Arijit Sinha Department of General Medicine, Murshidabad
More informationANAEMIA MANAGEMENT: THE KDIGO RECOMMENDATIONS Patrick S. Parfrey, St. John s, Canada
ANAEMIA MANAGEMENT: THE KDIGO RECOMMENDATIONS Patrick S. Parfrey, St. John s, Canada Chair: Kai- Uwe Eckardt, Erlangen, Germany Pierre- Yves Martin, Geneva, Switzerland Prof. Patrick S. Parfrey Division
More informationObjectives. Current WHO Definition of Anemia. Implication for Clinical Practice 10/8/18. Prevalence of Iron Deficiency in Women Undergoing Surgery
Pre-operative Anemia Clinic Dr Mike Scott MB ChB FRCP FRCA FFICM Professor in Anesthesiology and Critical Care Medicine Divisional Lead for Critical Care Medicine VCU Health System, Richmond, VA Professor
More informationCurrent situation and future of renal anemia treatment. FRANCESCO LOCATELLI
Antalya May 20, 2010 12 National Congress of Turkish Society of Hypertension and Renal Disease Current situation and future of renal anemia treatment. FRANCESCO LOCATELLI Department of Nephrology, Dialysis
More informationIron losses in dialysis patients exceed dietary absorption of
Acute Injury with Intravenous Iron and Concerns Regarding Long-Term Safety Kalkidan Bishu and Rajiv Agarwal Division of Nephrology, Department of Medicine, Indiana University School of Medicine, and Richard
More informationWilliam E. Strauss *, Naomi V. Dahl, Zhu Li, Gloria Lau and Lee F. Allen
Strauss et al. BMC Hematology (2016) 16:20 DOI 10.1186/s12878-016-0060-x RESEARCH ARTICLE Open Access Ferumoxytol versus iron sucrose treatment: a post-hoc analysis of randomized controlled trials in patients
More informationFDA Advisory Committee Briefing Document
FDA Advisory Committee Briefing Document Drug Safety and Risk Management Committee February 1, 2008 Prepared by the Division of Medical Imaging and Hematology Products/Office of Oncology Drug Products/Office
More informationCAN WE PREDICT THE RISK FOR ADVERSE EVENTS? Andrzej Wiecek, Katowice, Poland
CAN WE PREDICT THE RISK FOR ADVERSE EVENTS? Andrzej Wiecek, Katowice, Poland Chair: Kai- Uwe Eckardt, Erlangen, Germany Pierre- Yves Martin, Geneva, Switzerland Prof. Andrzej Więcek Departm ent of Nephrology,
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Centre for Clinical Practice
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice Review consultation document Review of Clinical Guideline (CG) CG 114: Anaemia management in Chronic Kidney Disease. Background
More information